
در تولید دارو, Tablet disintegration and dissolution are two different tests used to evaluate tablet performance. Disintegration measures how quickly a tablet breaks apart after contacting a liquid, while dissolution measures how much of the ماده فعال دارویی (API) goes into solution over time. به زبان ساده, disintegration tells you whether the tablet breaks up; dissolution tells you how the drug is released into the test medium.
These two results can be related, but they do not always match. A tablet may disintegrate quickly but still show slow dissolution because of poor API solubility, large particle size, poor wettability, excessive lubrication, or formulation factors. برعکس, a tablet with slower disintegration may still meet its dissolution requirements depending on the drug and dosage-form design.
برای تولید کنندگان دارو, understanding this difference is important when investigating tablet disintegration or dissolution problems. This article explains what each test actually shows, why their results can diverge, and how formulation, نیروی فشرده سازی, tablet porosity, تجزیه کننده, روانکاری, and other manufacturing factors can affect tablet performance.

طبق تعریف, disintegration testing (USP <701>) assesses whether an immediate‑release tablet breaks into smaller fragments within a specified time in liquid (usually water). Dissolution testing (USP <711>) measures how much of the active drug goes into solution over time under controlled conditions. به زبان ساده:
Disintegration is a mechanical break-up process. Without proper disintegration, only the API near the tablet surface can dissolve. Even if a tablet disintegrates fully, در انحلال depends on drug properties (حلالیت, اندازه ذرات, wettability) and test conditions. در عمل, the two tests often correlate but can diverge. به عنوان مثال, a tablet might break up rapidly (short disintegration time) but still release drug slowly if the API is poorly soluble. برعکس, a tablet might disintegrate slowly (long disintegration time) but still meet dissolution specs if the drug dissolves readily once particles are wetted.
The table below concisely compares the two tests:
| جنبه | Disintegration Test | Dissolution Test |
| اندازه گیری کنید | Physical breakup of tablet into small pieces | Amount (%) of drug released into solution over time |
| هدف | Confirm tablet will disintegrate in GI tract | Confirm tablet releases drug at intended rate |
| تجهیزات | USP Basket-Rack (tube assembly, 29–32 cycles/min) | USP Dissolution Apparatus (به عنوان مثال. دست و پا زدن, basket) |
| نتیجه | Pass/Fail (all tablets must break up) | Continuous profile (به عنوان مثال. % dissolved at 15, 30 دقیقه) |
| Typical Timeframe | 15–60 minutes per pharmacopeia | 30–60+ minutes (product-specific) |
| Compliance Basis | Monograph or compendial limits on max time | Monograph % آزاد کردن (به عنوان مثال. Q ≥ X % in Y min) |
| Correlation | “No disintegration = No dissolution”, but the converse isn’t guaranteed | Depends on formulation/excipients; influenced by solubility, و غیره. |
| Affected by | Binder level, disintegrant type, سختی, coating thickness | API solubility, surface area, مواد کمکی, test medium, and also tablet hardness/lubricants |
| Analytical Role | Quality check that tablet breaks up (قوام دسته ای) | Performance test (قابل دسترسی, قوام دسته ای) |
| مقررات | USP <701>, Ph.Eur. 2.9.1 (تجزیه) | USP <711> (و <1094> for capsules), Ph.Eur. 2.9.3 |
به طور خلاصه: Fast disintegration ≠ fast dissolution unless the drug is soluble enough. As one expert review states, “Wetting and subsequent disintegration of the powder compact is the first step towards liberation of the API… without disintegration only the API near the surface… dissolves”. Thus a full tablet disintegration is usually needed for consistent dissolution, but other factors govern how quickly the drug then dissolves.

شکل: Tablet → water penetration → disintegration → particle exposure → dissolution → drug release. Effective disintegration increases surface area for dissolution.
همانطور که در بالا ذکر شد, disintegration is only the اول step towards drug release. A tablet can meet disintegration criteria (pass USP <701>) yet still fail dissolution if the drug fails to dissolve. برعکس, some formulations (like modified-release or mucoadhesive tablets) may intentionally not fully disintegrate – yet they dissolve as designed. در عمل, we often see these patterns:

A tablet’s disintegration test measures how quickly liquid penetrates and breaks apart the tablet. In the standard apparatus, tablets sit in fluid on a disintegration tester; springs or perforated disks help agitate the sample. نکات کلیدی:
In immediate‐release tablets, تجزیه کننده (به عنوان مثال. کراسپوویدون, کراسکارملوز) promote rapid breakup. به عنوان مثال, Markus Markl and Greg Zeitler note that disintegrants create small granules and expose particles for dissolution. If a tablet fails disintegration (takes too long or doesn’t break), that indicates a formulation or equipment issue (به عنوان مثال. excessive binder or force). با این حال, even a fast‑disintegrating tablet may not meet dissolution specs if the drug is insoluble or protected by coating.

A tablet’s dissolution test evaluates drug release kinetics into a specified fluid (often water or buffer). Key aspects:
For immediate-release products, dissolution is the in vitro surrogate for in vivo drug availability. FDA guidance explains that dissolution tests (USP <711>) ensure consistent product quality and bioequivalence. Unlike disintegration, dissolution directly measures the amount of drug ready to be absorbed, and reflects both tablet breakup and API behavior. به طور خلاصه, dissolution answers: “How much active ingredient actually dissolves over time?”

Different factors can cause a tablet to disintegrate and dissolve at mismatched rates. Below are 8 key causes of divergence. Each cause is explained with mechanism, likely test pattern, and what to investigate.
By analyzing each cause (with mechanism and expected outcomes), one can prioritize what to check when disintegration vs dissolution do not match expectations. به عنوان مثال, if tablets dissolve very slowly but disintegrate normally, focus on API properties or dissolution medium. If tablets barely break up, focus on formulation (binder/disintegrant) and compression.
The table below summarizes typical test outcome combinations and suggests where to look. These are general patterns; always compare against product-specific specifications and release mechanisms.
| Disintegration Result | Dissolution Result | What to Check |
| سریع (short time) | سریع (meets spec) | Likely normal – confirm both meet product criteria. |
| سریع | آهسته or incomplete | Check API solubility, اندازه ذرات, روان کننده; ensure dissolution method is correct. |
| آهسته | آهسته (fails spec) | Likely formulation/compression issue – check hardness, کلاسور, تجزیه کننده, & تخلخل. |
| آهسته | Acceptable (meets spec) | Compare against spec: if dissolution meets spec, this may be allowed; still check if compaction too high. |
| متغیر | متغیر | Inconsistent process: check manufacturing controls (به عنوان مثال. تنوع وزن, مخلوط کردن) and test consistency. |
به عنوان مثال, a fast disintegration but slow dissolution often points to a low-solubility API or excessive hydrophobic lubricant – the tablet breaks up but drug goes into solution sluggishly. برعکس, a slow disintegration and slow dissolution suggest too strong or too dense a tablet. If disintegration is slow but dissolution actually meets product requirements, review whether the disintegration limit is overly strict for this formulation. Variable results usually mean batch-to-batch inconsistency or test error.
When tests diverge from expectations, a systematic investigation is needed. Here’s a recommended workflow with key checks (inspired by GMP Out-of-Spec procedures):
Throughout the troubleshooting, document each check. Below is a checklist of actions:
This systematic approach—from lab method to formulation to equipment—helps pinpoint why results diverge and ensures robust tablets.
Tablet press settings and tooling can significantly influence both tests. Key manufacturing variables and their effects include:
| Manufacturing Variable | Tablet Property Affected | Effect on Disintegration/Dissolution |
| Compression force | سختی, تراکم, Porosity | Higher force → harder, less porous tablets → slower disintegration and dissolution. |
| نیروی پیش فشرده سازی | Tablet uniformity | Pre-compression consolidates fill → often better consistency and less capping; can slightly reduce disintegration if overused. |
| سرعت برجک (زمان سکونت) | Dwell time per tablet | Faster speed = shorter dwell time → less densification → softer tablets (may dissolve faster, but weight variation risk). Slower speed = longer dwell → harder tablets. |
| Feeding consistency | تنوع وزن | Fluctuations cause dose and dissolution variability. Uniform feeding yields consistent tablet weight and content. |
| Blending time | یکنواختی محتوا | Inadequate mixing can leave pockets of disintegrant or binder → variability in test results. |
| Lubrication process | Surface hydrophobicity | Longer blending with Mg-stearate coats particles more thoroughly → wetting slowed → slower dissolution. |
| Tooling condition | Tablet shape/surface | Worn punches (لبه های برش خورده) or embossing changes can affect tablet porosity and breakage patterns; can alter disintegration behavior. |
به عنوان مثال, نیروی فشرده سازی is a critical lever: increasing force will usually boost tablet hardness and reduce porosity, making water penetration slower. برعکس, a very high turret speed (زمان اقامت کوتاه) might produce slightly softer tablets that release drug faster (though at risk of weight fluctuations). Jinlu’s literature (به عنوان مثال. on تراکم زمان سکونت) explains how speed and turret design influence dwell. به همین ترتیب, یکنواخت تغذیه and proper lubrication ensure consistent tablet surfaces; any hiccup in these can cause unpredictable dissolution values.
آرefer to Jinlu’s ماشین مطبوعاتی product pages for compression settings, پیش فشرده سازی ویژگی ها, و ابزار تبلت solutions to see how adjustable parameters can help achieve the desired tablet properties.
Regulators recognize that in some cases a disintegration test may suffice for immediate-release tablets, but strict criteria apply. FDA Q6A guidance notes that for highly soluble drugs in certain IR formulations, one might justify using disintegration as a surrogate if supported by data. در عمل, this is rare and requires demonstrating by test data that the drug is “truly rapidly dissolving.” USP <701> explicitly focuses on tablet breakup, در حالی که <711> remains the gold standard for drug release.
به عبارت دیگر, disintegration can never automatically replace dissolution testing. Any substitution must be justified by regulatory submissions, به عنوان مثال. by showing the drug is Class I (high solubility, high permeability) and formulation is “simple”. حتی آن زمان, pharmacopeia chapters suggest the disintegration test conditions must exactly match the dissolution specification (به عنوان مثال, متوسط, apparatus). Companies often keep both tests for full assurance.
Tablet disintegration and dissolution measure different aspects of tablet performance. Disintegration shows how a tablet breaks apart, while dissolution reveals how much of the active drug enters solution over time. When results diverge, the cause may lie in API properties, تدوین, compression settings, or testing conditions.
برای تولید کنندگان دارو, understanding these differences is essential for maintaining consistent tablet quality. A well-controlled compression process helps reduce manufacturing variability, but achieving the desired dissolution profile also requires suitable formulation design and appropriate quality testing.
Need a more consistent tablet compression process?
و انتخاب jeinlu, we provide رایانه لوحی دوار ماشین آلات and customized pharmaceutical manufacturing solutions. Whether you’re developing a new tablet formulation, ارتقاء تجهیزات موجود, or scaling up production, our engineering team can help you evaluate suitable compression force, پیش فشرده سازی, تغذیه, and production capacity requirements.
امروز با جینلو پکینگ تماس بگیرید to discuss your tablet specifications, خصوصیات مادی, و اهداف تولید.
Tablet disintegration measures how quickly a tablet breaks apart into smaller particles. Dissolution measures how much of the API is released into the test medium and becomes dissolved over time. They are related tests, but they evaluate different stages of tablet performance.
بله. Fast disintegration does not necessarily mean fast dissolution. Poor API solubility, large particle size, poor wettability, excessive lubrication, or formulation factors can cause slow dissolution even when the tablet breaks apart quickly.
بله. Higher tablet hardness can reduce porosity and make liquid penetration more difficult, potentially increasing disintegration time and slowing dissolution. با این حال, the actual effect depends on the formulation and product design.
Compression force can change tablet hardness, تخلخل, and internal structure. Excessive compression may produce a denser tablet that takes longer to disintegrate, while insufficient compression can result in weak tablets with poor mechanical strength.
Common causes include poor API solubility or wettability, large API particle size, formulation issues, excessive lubrication, high tablet density, unsuitable coating, and inappropriate dissolution test conditions. Both formulation and manufacturing variables should be investigated.
Disintegration time only describes how quickly the tablet breaks apart. Dissolution also depends on API properties, اندازه ذرات, surface area, wettability, formulation composition, and the conditions of the dissolution method. از این رو, similar disintegration times do not guarantee similar dissolution profiles.
بله. Tablet porosity influences how easily the dissolution medium penetrates the tablet and how quickly particles become exposed to the liquid. Changes in compression and formulation can alter porosity and consequently affect disintegration and dissolution.
In some specific cases, disintegration may be used instead of dissolution testing when applicable regulatory and product-development criteria are satisfied. It should not be assumed that a passing disintegration test can generally replace dissolution testing.
First verify the dissolution method and test conditions, including the apparatus, متوسط, دما, تحریک, نمونه برداری, and analytical procedure. If the test is confirmed, investigate API properties, تدوین, روانکاری, دانه, compression parameters, سختی قرص, تخلخل, و پوشش.
Manufacturing parameters such as compression force, پیش فشرده سازی, سرعت برجک, زمان سکونت, feeding consistency, روانکاری, and tooling condition can change tablet properties. These changes may affect hardness, تخلخل, تجزیه, and ultimately dissolution performance.
مراجع:
1.Dissolution Testing of Immediate Release Solid Oral Dosage Forms —— FDA
2.Compilation of FDA Guidance and Resources for in vitro Dissolution Testing of Immediate Release Solid Oral Dosage Forms —— FDA
3.Exploring the performance-controlling tablet disintegration mechanisms for direct compression formulations —— PubMed
4.Supporting Information for Dissolution / انتشار دارو / Disintegration Tests —— USP
5.ICH Q4B Annex 5 Disintegration Test —— آژانس دارویی اروپا
6.A Review of Disintegration Mechanisms and Measurement Techniques —— Springer Nature

مد کوچک, بنیانگذار Jinlupacking, به ارمغان می آورد 20 سالها تخصص در بخش ماشین آلات دارویی. تحت رهبری او, جینلو تبدیل به یک تامین کننده قابل اعتماد با طراحی یکپارچه شده است, تولید, و فروش. پتی مشتاق به اشتراک گذاری دانش عمیق خود در صنعت است تا به مشتریان کمک کند تا پیچیدگی های بسته بندی دارو را طی کنند., اطمینان حاصل شود که آنها نه تنها تجهیزات را دریافت می کنند, اما یک مشارکت خدمات یک مرحله ای واقعی متناسب با اهداف تولید آنها.



